Orion Portfolio Solutions LLC boosted its position in Balchem Co. (NASDAQ:BCPC – Free Report) by 123.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,266 shares of the basic materials company’s stock after purchasing an additional 1,802 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Balchem were worth $575,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Balchem in the 3rd quarter valued at $35,000. GAMMA Investing LLC lifted its position in shares of Balchem by 73.4% during the 3rd quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 356 shares during the period. Blue Trust Inc. lifted its position in shares of Balchem by 642.5% during the 3rd quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 726 shares during the period. TD Asset Management Inc bought a new stake in shares of Balchem during the 2nd quarter valued at $200,000. Finally, Heritage Family Offices LLP bought a new stake in shares of Balchem during the 2nd quarter valued at $206,000. 87.91% of the stock is currently owned by institutional investors.
Balchem Price Performance
Balchem stock opened at $172.35 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.90 and a current ratio of 2.98. Balchem Co. has a 52 week low of $135.84 and a 52 week high of $186.03. The stock has a market capitalization of $5.60 billion, a P/E ratio of 46.33, a price-to-earnings-growth ratio of 5.32 and a beta of 0.67. The stock has a fifty day moving average of $175.26 and a 200-day moving average of $169.44.
Balchem Increases Dividend
Analysts Set New Price Targets
A number of research firms have recently weighed in on BCPC. HC Wainwright upped their target price on Balchem from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, November 4th. StockNews.com upgraded Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.
Check Out Our Latest Stock Report on BCPC
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Articles
- Five stocks we like better than Balchem
- Investing in the High PE Growth Stocks
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- P/E Ratio Calculation: How to Assess Stocks
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- The Risks of Owning Bonds
- Salesforce’s Clear Path to $400 and Beyond
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.